36. Gudjonsson JE, Johnston A., and Ellis CN (2012). Novel systemic drugs under investigation for the treatment of psoriasis. J Am Acad Dermatol , 67 ( 1 ), 139–147.
37. Nickoloff BJ and Nestle FO (2004). Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest , 113 ( 12 ), 1664–1675.
38. Gudjonsson JE, Johnston A., Sigmundsdottir H. et al. (2004). Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol , 135 ( 1 ), 1–8.
39. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses - PubMed.
Maybe you are interested!
-
Evaluation of treatment results and changes in some immune factors in patients with common psoriasis treated with narrow band ultraviolet light - 1 -
Evaluation of the treatment results of Schatzker type V-VI tibial plateau fractures by combining minimal bone fusion and external ring fixation under fluoroscopy - 13 -
Evaluation of treatment results and changes in some immune factors in patients with common psoriasis exposed to narrow band ultraviolet light - 2 -
Management Status of Tcm Results Evaluation Through NCBH Form Table 2.9: Current Status of Evaluation of Professional Team Performance Results Through Form -
Evaluation of the effectiveness of selective tibial nerve resection in the treatment of lower limb muscle spasticity sequelae - 19
<https://pubmed.ncbi.nlm.nih.gov/18039949/>, accessed: August 5, 2021.
40. Ten Bergen LL, Petrovic A., Krogh Aarebrot A. et al. (2020). The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol , 92 ( 4 ), e12946.
41. Pappu R., Ramirez-Carrozzi V., Ota N. et al. (2010). The IL-17 Family Cytokines in Immunity and Disease. J Clin Immunol , 30 ( 2 ), 185–195.
42. Li J., Chen X., Liu Z. et al. (2007). Expression of Th17 cytokines in skin lesions of patients with psoriasis. J Huazhong Univ Sc Technol , 27 ( 3 ), 330–332.
43. Papp KA, Leonardi C., Menter A. et al. (2012). Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med , 366 ( 13 ), 1181–1189.
44. Leonardi C., Matheson R., Zachariae C. et al. (2012). Anti- interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med , 366 ( 13 ), 1190–1199.
45. Martin DA, Towne JE, Kricorian G. et al. (2013). The Emerging Role of Interleukin-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings. J Invest Dermatol , 133 ( 1 ), 17–26.
46. Lynde CW, Poulin Y., Vender R. et al. (2014). Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. Journal of the American Academy of Dermatology , 71 ( 1 ), 141–150.
47. Blauvelt A. and Chiricozzi A. (2018). The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol , 55 ( 3 ), 379–390.
48. Weaver CT, Hatton RD, Mangan PR et al. (2007). IL-17 Family Cytokines and the Expanding Diversity of Effector T Cell Lineages. Annu Rev Immunol , 25 ( 1 ), 821–852.
49. Iwakura Y., Ishigame H., Saijo S. et al. (2011). Functional Specialization of Interleukin-17 Family Members. Immunity , 34 ( 2 ), 149–162.
50. Kagami S., Rizzo HL, Kurtz SE et al. (2010). IL-23 and IL-17A, but Not IL-12 and IL-22, Are Required for Optimal Skin Host Defense against Candida albicans. The Journal of Immunology , 185 ( 9 ), 5453–5462.
51. Piskin G., Sylva-Steenland RMR, Bos JD et al. (2006). In Vitro and In Situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis Lesions: Enhanced Expression in Psoriatic Skin. The Journal of Immunology , 176 ( 3 ), 1908–1915.
52. Rizzo HL, Kagami S., Phillips KG et al. (2011). IL-23– Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A. The Journal of Immunology , 186 ( 3 ), 1495–1502.
53. Res PCM, Piskin G., Boer OJ de et al. (2010). Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis. PLOS ONE , 5 ( 11 ), e14108.
54. Blauvelt A. (2007). New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-β1. Expert Review of Dermatology , 2 ( 1 ), 69–78.
55. Kryczek I., Bruce AT, Gudjonsson JE et al. (2008). Induction of IL-17+ T Cell Trafficking and Development by IFN-γ: Mechanism and Pathological Relevance in Psoriasis. The Journal of Immunology , 181 ( 7 ), 4733–4741.
56. Nograles KE, Zaba LC, Guttman-Yassky E. et al. (2008). Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol , 159 ( 5 ), 1092–1102.
57. Harper E.G., Guo C., Rizzo H. et al. (2009). Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis. Journal of Investigative Dermatology , 129 ( 9 ), 2175–2183.
58. Kagami S., Rizzo H.L., Lee JJ et al. (2010). Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis. Journal of Investigative Dermatology , 130 ( 5 ), 1373–1383.
59. Zhang L., Yang X.-Q., Cheng J. et al. (2010). Increased Th17 cells are accompanied by FoxP3+ Treg cell accumulation and correlated with psoriasis disease severity. Clinical Immunology , 135 ( 1 ), 108–117.
60. Arican O., Aral M., Sasmaz S. et al. (2005). Serum levels of TNF- alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm , 2005 ( 5 ), 273–279.
61. Caproni M., Antiga E., Melani L. et al. (2009). Serum Levels of IL-17 and IL-22 Are Reduced by Etanercept, but not by Acitretin, in Patients with Psoriasis: a Randomized-Controlled Trial. Journal of Clinical Immunology , 29 ( 2 ), 210–214.
62. Takahashi H., Tsuji H., Hashimoto Y. et al. (2010). Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol , 35 ( 6 ), 645–649.
63. Yilmaz SB, Cicek N., Coskun M. et al. (2012). Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res , 304 ( 6 ), 465–469.
64. Coimbra S., Oliveira H., Reis F. et al. (2010). Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumor necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy: Psoriasis vulgaris cytokines and PUVA/NB-UVB therapy. British Journal of Dermatology , 163 ( 6 ), 1282–1290.
65. Zaba LC, Suárez-Faridas M., Fuentes-Duculan J. et al. (2009). Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol , 124 ( 5 ), 1022-1010.e1–395.
66. Fitz L., Zhang W., Soderstrom C. et al. (2018). Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis. Clin Exp Dermatol , 43 ( 7 ), 790–797.
67. Oppmann B., Lesley R., Blom B. et al. (2000). Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity , 13 ( 5 ), 715–725.
68. Sheibanie AF, Tadmori I., Jing H. et al. (2004). Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J , 18 ( 11 ), 1318–1320.
69. Stockinger B. and Veldhoen M. (2007). Differentiation and function of Th17 T cells. Curr Opin Immunol , 19 ( 3 ), 281–286.
70. Blauvelt A. (2008). T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol , 128 ( 5 ), 1064–1067.
71. Tesmer LA, Lundy SK, Sarkar S. et al. (2008). Th17 cells in human disease. Immunol Rev , 223 , 87–113.
72. Gerosa F., Baldani-Guerra B., Lyakh LA et al. (2008). Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med , 205 ( 6 ), 1447–1461.
73. Uyemura K., Yamamura M., Fivenson D.F. et al. (1993). The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol , 101 ( 5 ), 701–705.
74. Boniface K., Blom B., Liu Y.-J. et al. (2008). From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev , 226 , 132–146.
75. Yen D., Cheung J., Scheerens H. et al. (2006). IL-23 is essential for mediating T cell-colitis and promoting inflammation via IL-17 and IL-6. J Clin Invest , 116 ( 5 ), 1310–1316.
76. Torti DC and Feldman SR (2007). Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol , 57 ( 6 ), 1059–1068.
77. Wolk K., Witte E., Wallace E. et al. (2006). IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol , 36 ( 5 ), 1309–1323.
78. Mudigonda P., Mudigonda T., Feneran AN et al. (2012). Interleukin-23 and interleukin-17: Importance in pathogenesis and therapy of psoriasis. Dermatology Online Journal , 18 ( 10 ).
79. Kagami S., Rizzo HL, Lee JJ et al. (2010). Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol , 130 ( 5 ), 1373–1383.
80. Guttman-Yassky E., Lowes MA, Fuentes-Duculan J. et al. (2008). Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol , 181 ( 10 ), 7420–7427.
81. Chan J.R., Blumenschein W., Murphy E. et al. (2006). IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med , 203 ( 12 ), 2577–2587.
82. Kopp T., Lenz P., Bello-Fernandez C. et al. (2003). IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol , 170 ( 11 ), 5438–5444.
83. Liu Y., Helms C., Liao W. et al. (2008). A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet , 4 ( 3 ), e1000041.
84. Krueger GG, Langley RG, Leonardi C. et al. (2007). A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med , 356 ( 6 ), 580–592.
85. Bajaj S., Gautam R.K., Khurana A. et al. (2017). Effect of narrow band ultraviolet B phototherapy on T helper 17 cell specific cytokines (interleukins-17, 22 and 23) in psoriasis vulgaris. Journal of Dermatological Therapy , 28 ( 1 ), 14–17.
86. Keffer J., Probert L., Cazlaris H. et al. (1991). Transgenic mice express human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J , 10 ( 13 ), 4025–4031.
87. Chiricozzi A., Guttman-Yassky E., Suárez-Faridas M. et al. (2011). Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol , 131 ( 3 ), 677–687.
88. Johnston A., Fritz Y., Dawes S. M. et al. (2013). Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol , 190 ( 5 ), 2252–2262.
89. Ogawa E., Sato Y., Minagawa A. et al. (2018). Pathogenesis of psoriasis and development of treatment. The Journal of Dermatology , 45 ( 3 ), 264–272.
90. Chaudhari U., Romano P., Mulcahy LD et al. (2001). Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet , 357 ( 9271 ), 1842–1847.
91. Papp KA, Poulin Y., Bissonnette R. et al. (2012). Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol , 66 ( 2 ), e33-45.
92. Swindell WR, Xing X., Stuart PE et al. (2012). Heterogeneity of inflammation and cytokine networks in chronic plaque psoriasis. PLOS ONE , 7 ( 3 ), e34594.
93. Tsoi LC, Spain SL, Knight J. et al. (2012). Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet , 44 ( 12 ), 1341–1348.
94. Dowlatshahi EA, van der Voort EAM, Arends LR et al. (2013). Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. British Journal of Dermatology , 169 ( 2 ), 266–282.
95. Mussi A., Bonifati C., Carducci M. et al. (1997). Serum TNF- alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents , 11 ( 3 ), 115–118.
96. Kyriakou A., Patsatsi A., Vyzantiadis T.-A. et al. (2014). Serum levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity. J Immunol Res , 2014 , 467541.
97. Abdel-Hamid MF, Aly DG, Saad NE et al. (2011). Serum levels of interleukin-8, tumor necrosis factor-α and γ-interferon in Egyptian psoriatic patients and correlation with disease severity: IL-8, TNF-α and IFN-γ correlation with psoriasis. The Journal of Dermatology , 38 ( 5 ), 442–446.
98. ROSSI MT, VENTURINI M., ZANCA A. et al. (2018). Serum levels of tumor necrosis factor-alpha in patients with psoriasis before, during and after narrow-band UVB phototherapy. Giornale Italiano di Dermatologia e Venereologia , 153( 1 ), 1–4.
99. Akçali C., Guven EH, Kirtak N. et al. (2014). Serum concentrations of interleukin-2 and tumor necrosis factor-α under cyclosporine versus acitretin treatment in plaque-type psoriasis. Journal of International Medical Research , 42 ( 5 ), 1118–1122.
100.Ozawa M., Ferenczi K., Kikuchi T. et al. (1999). 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med , 189 ( 4 ), 711–718.
101.Lapolla W., Yentzer BA, Bagel J. et al. (2011). A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol , 64 ( 5 ), 936–949.
102.Gupta R., Debbaneh M., Butler D. et al. (2013). The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis. J Vis Exp , ( 77 ).
103.Perry HO, Soderstrom CW, and Schulze RW (1968). The Goeckerman treatment of psoriasis. Arch Dermatol , 98 ( 2 ), 178–182.
104. Parrish JA and Jaenicke KF (1981). Action spectrum for phototherapy of psoriasis. J Invest Dermatol , 76 ( 5 ), 359–362.
105.Jennifer A. Cafardi, Brian P. Pollack, and Craig A. Elmets (2012). Phototherapy. Fitzpatrick's Dermatology in General Medicine . Eighth Edition, The McGraw-Hill Companies, Inc, 2841–2850.